MedPath

A randomised, single blinded, prospective, observational study of molecular biological effects of xenon inhalation used for early preconditioning in humans undergoing coronary artery bypass grafting

Conditions
CABG
10011082
Registration Number
NL-OMON31122
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Age range: 18 years or older
Patients who have to undergo elective cardiac surgery (CABG with or without valve surgery)
Written informed consent
All inclusion criteria must be met; otherwise the patient cannot be enrolled into the study

Exclusion Criteria

Age range: < 18 years
Emergency operations
Pregnancy
Severe COPD
Informed written consent missing
SaO2 < 90% (room atmosphere)
Presumed non-cooperatives
Legal incapacity
Any clinical condition which does not justify study participation in the investigator's opinion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The present application of xenon seeks to investigate the mechanisms behind<br /><br>xenon preconditioning in humans. This will be done by examination of 3<br /><br>myocardial tissue probes (called A, B and C) per patient (numbered 1, 2, 3,<br /><br>etc.) in a molecular laboratory setting detecting activity of PKC-e, p38MAPK,<br /><br>JNK and ERK. For transport purposes the probes will be preserved in Eppendorf®<br /><br>cups placed into liquid nitrogen (-30 °C). </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Troponin T, CPK, CPK-MB, pro-BNP and S-100 protein levels will be examined both<br /><br>before operation and during the first 24 hours of the ICU period after the<br /><br>operation.</p><br>
© Copyright 2025. All Rights Reserved by MedPath